ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as at

ADDEX THERAPEUTICS LTD

INDEX TO UNAUDITED INTERIM CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

3 Report | Interim Condensed Consolidated Financial Statements

ADDEX THERAPEUTICS LTD

Unaudited Interim Condensed Consolidated

as at September 30, 2020 and December 31,

The accompanying notes form an integral

part of these consolidated financial statements.

3 Report | Interim Condensed Consolidated Financial Statements

ADDEX THERAPEUTICS LTD

Unaudited Interim Condensed Consolidated

Statements of Comprehensive Loss

for the three-month and nine-month periods

ended September 30, 2020

The accompanying notes form an integral

part of these consolidated financial statements.

3 Report | Interim Condensed Consolidated Financial Statements

ADDEX THERAPEUTICS LTD

Unaudited Interim Condensed Consolidated

Statements of Changes in Equity

For the nine-month period ended September 30,

The accompanying notes form an integral

part of these consolidated financial statements.

3 Report | Interim Condensed Consolidated Financial Statements

ADDEX THERAPEUTICS LTD

Unaudited Interim Condensed Consolidated

Statements of Changes in Equity

For the three-month period ended September 30,

Amounts in Swiss francs

The accompanying notes form an integral

part of these consolidated financial statements.

3 Report | Interim Condensed Consolidated Financial Statements

ADDEX THERAPEUTICS LTD

Unaudited Condensed Consolidated Statements

of Changes in Equity

For the three-month period ended September 30,

Amounts in Swiss francs

The accompanying notes form an integral

part of these consolidated financial statements.

3 Report | Interim Condensed Consolidated Financial Statements

ADDEX THERAPEUTICS LTD

Unaudited Interim Condensed Consolidated

Statements of Cash Flows

for the nine-month period ended September 30,

The accompanying notes form an integral

part of these consolidated financial statement

Quarter 3 Report | Interim

Condensed Consolidated Financial Statements | Notes

Unaudited Notes to the Interim Condensed

Consolidated Financial Statements

1. General information

Addex Therapeutics Ltd (the "Company"), formerly

Addex Pharmaceuticals Ltd, and its subsidiaries (together, the "Group") are a clinical stage pharmaceutical group

applying its leading allosteric modulator drug discovery platform to discovery and development small molecule pharmaceutical products,

with an initial focus on central nervous system disorders.

The Company is a Swiss stockholding corporation domiciled c/o

Addex Pharma SA, Chemin des Aulx 12, CH1228 Plan-les-Ouates, Geneva, Switzerland and the parent company of Addex Pharma SA,

Addex Pharmaceuticals France SAS and Addex Pharmaceuticals Inc., company created on May 29, 2019 registered in Delaware

with its principal business location in San Francisco, California, United States. Its registered shares are traded at the SIX,

Swiss Exchange, under the ticker symbol ADXN. On January 29, 2020, the Group listed on the Nasdaq Stock Market, American

Depositary Shares (ADSs) under the symbol "ADXN", without a new issuance of securities. ADSs represents shares that

continue to be admitted to trading on SIX Swiss Exchange.

These condensed consolidated financial statements have been

approved for issuance by the Board of Directors on October 30, 2020.

2. Basis of preparation

These condensed consolidated interim financial statements for

the three month and nine month periods ended September 30, 2020, have been prepared under the historic cost convention and

in accordance with IAS 34 "Interim Financial Reporting" and are presented in a format consistent with the consolidated

financial statements under IAS 1 "Presentation of Financial Statements". However, they do not include all of the notes

that would be required in a complete set of financial statements. Thus, this interim financial report should be read in conjunction

with the consolidated financial statements for the year ended December 31, 2019.

Interim financial results are not necessarily indicative of

results anticipated for the full year. The preparation of these unaudited condensed consolidated interim financial statements

made in accordance with IAS 34 requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities

and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues

and expenses during the reporting period. Although these estimates are based on management's best knowledge of current events

and actions, actual results ultimately may differ from those estimates. The areas involving a higher degree of judgment which

are significant to the condensed consolidated interim financial statements are disclosed in note 4 to the consolidated financial

statements for the year ended December 31, 2019.

A number of new or amended standards and interpretations became

applicable for financial periods beginning on or after January 1, 2020. The Group noted that the latter did not have a material

impact on the Group's financial position or disclosures made in the condensed consolidated interim financial statements.

Due to rounding, numbers presented throughout these condensed

consolidated financial statements may not add up precisely to the totals provided. All ratios and variances are calculated using

the underlying amount rather than the presented rounded amount.

Report | Interim Condensed Consolidated Financial Statements | Notes

3. Critical accounting estimates and judgments

The Group makes estimates and assumptions concerning the future.

These estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations

of future events that are believed to be reasonable under the circumstances. The resulting accounting estimates will, by definition,

seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment

to the carrying amounts of assets and liabilities or may have had a significant impact on the reported results are disclosed below: